Illumina (ILMN) Stock
Key stats
- Market cap
- $42.20B
- Price / Earnings ratio
- 49.3x
- EPS (TTM)
- $5.40
- Volume
- Loading
- 52-week high
- $309.35
- 52-week low
- $94.00
- EPS vs analyst estimate
- +15.5%Q3 FY25 · $1.34 vs $1.16
- Next earnings report
- 29 Oct 2026
Source: third-party data provider, as of October 29, 2026
EPS estimate: analyst consensus
Compare with ILMN
Recent news

Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
ILMN

Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
ILMN

ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
ILMN

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
ILMN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 63.71
- MACD 12/26/9
- 8.30
- EMA 9 of MACD
- 8.95
- MACD histogram
- -0.64
- SMA 50
- $247.14
- Price above SMA 50
- EMA 50
- $249.47
- Price above EMA 50
- SMA 200
- $174.93
- Price above SMA 200
- EMA 200
- $186.83
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 28, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 12 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.36 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
ILMN

Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
ILMN

ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
ILMN

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
ILMN

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
ILMN

Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?
Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?
ILMN

REGN or ILMN: Which Is the Better Value Stock Right Now?
REGN or ILMN: Which Is the Better Value Stock Right Now?
ILMN

Is the Options Market Predicting a Spike in Illumina Stock?
Is the Options Market Predicting a Spike in Illumina Stock?
ILMN

Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
ILMN

3 Analysts, 3 Trades to Make Today
3 Analysts, 3 Trades to Make Today
ILMN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Illumina
As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jacob Thaysen Ph.D. | CEO, President & Director | 1975 |
| Mr. Ankur Dhingra CPA | Chief Financial Officer | 1976 |
| Mr. Kevin Carl Pegels | Chief of Global Operations | 1968 |
| Dr. Steven Barnard Ph.D. | Chief Technology Officer | 1961 |
| Mr. Scott Ericksen | VP & Chief Accounting Officer | 1973 |
| Mr. Mark Field | Chief Information Officer | 1971 |
| Mr. Conor Noel McNamara C.F.A. | VP of Investor Relations | — |
| Ms. Julie Ann Coletti J.D. | Chief Legal Officer | 1968 |
| Mr. Jakob Wedel | Chief Strategy & Corporate Development Officer | 1972 |
| Ms. Patricia Leckman | Senior VP & Chief People Officer | 1964 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 29, 2026
Technical indicators
- RSI 14
- 63.71
- MACD 12/26/9
- 8.30
- EMA 9 of MACD
- 8.95
- MACD histogram
- -0.64
- SMA 50
- $247.14
- Price above SMA 50
- EMA 50
- $249.47
- Price above EMA 50
- SMA 200
- $174.93
- Price above SMA 200
- EMA 200
- $186.83
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 28, 2026. Technical data, not a recommendation.
Analyst views
12 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $113.00
- Average
- $254.42
- High
- $310.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.3 | +6.4 | ||||||||||
| 2022 | -8.4 | -8.4 | +5.8 | -18.5 | -20.4 | -21.6 | +13.4 | -6.5 | -4.9 | +22.2 | -0.5 | -8.4 |
| 2023 | +6.6 | -8.0 | +17.1 | -10.6 | -2.8 | -5.8 | +2.1 | -12.7 | -18.5 | -19.8 | -4.4 | +26.8 |
| 2024 | +3.9 | -4.1 | -2.3 | -7.3 | -16.4 | +1.0 | +16.2 | +7.4 | +0.1 | +11.8 | -3.7 | -7.9 |
| 2025 | +1.4 | -32.3 | -5.8 | -1.0 | +7.5 | +17.7 | +4.6 | +5.6 | -2.9 | +20.8 | +9.6 | +1.9 |
| 2026 | +7.8 | -4.7 | -7.2 | +0.1 | +20.0 | +7.0 | +11.5 | +7.8 | +32.1 | +8.7 |



